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affecting one in ﬁve people over the course of their life. Currently
diagnosis is often based on the subjective opinion of health care profes-
sionals. The lack of an objective test increases the rate of mis- and
delayed-diagnosis, oftenwith people being later diagnosedwith bipolar
instead (Angst, 2007).
In an effort to identify the underlying mechanisms of MDD, recent
studies have attempted to elicit disease speciﬁc properties of the cingu-
late cortex. Mayberg et al. (1997) who found hypometabolism in the
rostal cingulate cortex predicted nonresponse to anti-depressants
while cortical thinning in the dorsal anterior cingulate cortex is linked
to clinical (Van Tol et al., 2013) and non-clinical cognitive trait markers
in MDD (Li et al., 2014).
Clinical concepts of patient subgroups tried to relate different in-
volvements of norepinephrine and serotonin transmitter systems to dif-
ferent clinical symptoms (Malhi et al., 2005). Furthermore functional
connectivity between the anterior insula and pregenual anterior cingu-
late cortex was found to be modulated by glutamatergic levels (Horn
et al., 2010) further suggesting a brain correlate of treatment selective
subgroups in depression. Taken together, we have seen growing evi-
dence of neurobiological alterations linked to depression, predicting
treatment response to transmitter speciﬁc drugs.
Recently it was shown that MR-based classiﬁcation is highly success-
ful in identifying patients (Lord et al., 2012) usingmachine learning tech-
niques and Redlich et al. (2014) showed that imaging based classiﬁcation
algorithms also work across countries and scanners. Thus the time seems
ripe to test the performance on an imaging supported decision algorithm,
which for the case of SSRI and SNRI so far remains largely intuitive.
Korgaonkar et al. (2015) now leverage data mining tools to identify
biomarkers capable of predicting who will respond to selective seroto-
nin reabsorption inhibitors (SSRIs) or serotonin–norepinephrine reup-
take inhibitors (SNRIs). They use a technique known as decision trees
to identify the treatment optionmost likely to succeed for an individual.
This technique is particularly well adapted to clinical settings as it canDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.12.002.
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example suggests that clinicians may in the future be able to inform
treatment choice based on surrogate markers of brain integrity. This is
an exciting advance as it offers the ability to tailor treatment strategies
to the individual in an objective manner, improving the likelihood of
successful treatment for individuals.
Such research represents an important proof of principle to over-
come translational roadblocks which so far disconnect ample amount
of evidence from non-invasive imaging studies and diagnostic clinical
applications. Within the last 20 years, the availability of clinical MR
systems has reached a critical mass where it becomes conceivable that
patients can undergo simple structural or functional brain scans within
the reach of their clinical environment. This infrastructural develop-
ment is paralleled by mass accumulation of evidence on certain typical
brain features which would underlie any neurobiologically derived
clinical evidence.
Looking toward clinical applications, current and future large-scale
imaging studies are uniquely equipped to advance knowledge into the
classiﬁcation of psychiatric patients. However, such an undertaking is
typically beyond the scope ofmost individual research groups. Research
in the ﬁeld of psychiatric neuroimaging would beneﬁt immeasurably
from adopting open data sharing practices, similar to those that enabled
rapid developments in genomics. Alreadywe have seen progress in data
sharing practices in clinical neuroimaging for other patient populations
such as dementia (Mueller et al., 2005).
Similar databases are currently generated around the globe, includ-
ing other diagnostic groups allowing quantitative diagnostic imaging
tests for affective disorders that are robust, speciﬁc and sensitive will
hopefully become a reality. Next to individualized treatment prediction
which may not accumulate the same quantities of data, the next steps
may further largely beneﬁt from trans-diagnostic databases. In such a
framework individual treatment responsivity may also be derived
from localization of speciﬁc impairments within a multidimensional
neurobiological framework irrespective of strict nosological categories.Disclosure
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